Biocept Company Profile (NASDAQ:BIOC)

About Biocept

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Industry, Sector and Symbol:

Sector: Medical
Industry: Medical Laboratories & Research
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: BIOC
CUSIP:

Key Metrics:

Previous Close: $0.58
50 Day Moving Average: $0.5877
200 Day Moving Average: $0.8402
52-Week Range: $0.49 - $2.76
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -1.10
P/E Growth: -0.0200
Market Cap: $14.92M
Outstanding Shares: 25,189,000
Beta: 2.04

Profitability:

Net Margins: -1,466.69%
Return on Equity: -764.73%
Return on Assets: -196.39%

Debt:

Debt-to-Equity Ratio: -6.10%
Current Ratio: 1.38%
Quick Ratio: 1.24%

Additional Links:

Companies Related to Biocept:

Consensus Ratings for Biocept (NASDAQ:BIOC) (?)

Ratings Breakdown:	1 Hold Rating, 3 Buy Ratings
Consensus Rating:	Buy (Score: 2.75)
Consensus Price Target:	$2.57 (333.41% upside)

Analysts' Ratings History for Biocept (NASDAQ:BIOC)

Show:

Date	Firm	Action	Rating	Price Target
8/31/2016	Rodman & Renshaw	Set Price Target	Buy	$2.50
8/3/2016	Feltl & Co.	Downgrade	Buy -> Hold
6/6/2016	Roth Capital	Initiated Coverage	Buy	$1.20
1/10/2016	HC Wainwright	Reiterated Rating	Buy	$4.00
1/21/2015	Aegis	Reiterated Rating	Buy

(Data available from 9/25/2014 forward)

Earnings History for Biocept (NASDAQ:BIOC)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/3/2016
8/2/2016	Q216	($0.22)	($0.20)			View	N/A
5/12/2016	Q116	($0.23)	($0.25)			View	Listen
3/9/2016	Q415	($0.26)	($0.24)	$76.00 million	$218.00 million	View	N/A
11/5/2015	Q315	($0.22)	($0.24)		$165.00 million	View	N/A
8/10/2015	Q215	($0.23)	($0.22)	$19.25 million	$76.77 million	View	Listen
5/12/2015	Q115	($0.61)	($0.37)			View	Listen
3/9/2015	Q414	($0.88)	($0.87)			View	N/A
11/13/2014		($0.82)	($0.87)			View	N/A
8/15/2014		($0.67)	($0.67)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Biocept (NASDAQ:BIOC)

Current Year EPS Consensus Estimate: $-0.81 EPS
Next Year EPS Consensus Estimate: $-0.54 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q2 2016	1	($0.22)	($0.22)	($0.22)
Q3 2016	2	($0.22)	($0.18)	($0.20)
Q4 2016	2	($0.20)	($0.18)	($0.19)
Q1 2017	1	($0.20)	($0.20)	($0.20)
Q2 2017	1	($0.19)	($0.19)	($0.19)
Q3 2017	1	($0.18)	($0.18)	($0.18)
Q4 2017	1	($0.17)	($0.17)	($0.17)

(Data provided by Zacks Investment Research)

Dividend History for Biocept (NASDAQ:BIOC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Biocept (NASDAQ:BIOC)

Insider Ownership Percentage: 6.80%
Institutional Ownership Percentage: 4.80%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
5/4/2016	Bruce Gerhardt	Director	Buy	25,000	$1.00	$25,000.00
5/4/2016	Claire Reiss	Major Shareholder	Buy	614,273	$1.00	$614,273.00
2/13/2015	David F Hale	Chairman	Buy	40,000	$1.25	$50,000.00
2/13/2015	Marsha Alpert Chandler	Director	Buy	2,000	$1.25	$2,500.00
2/13/2015	Michael W Nall	CEO	Buy	12,000	$1.25	$15,000.00

(Data available from 1/1/2013 forward)

Latest Headlines for Biocept (NASDAQ:BIOC)

Date	Headline
	Biocept, Inc. (NASDAQ:BIOC)'s Expectation Of $11.94 In Sales - Investor Newswire (NASDAQ:BIOC) www.investornewswire.com - September 24 at 8:05 AM
	Shares Of Biocept, Inc. (NASDAQ:BIOC) Expected To Hit $2.5 - Investor Newswire (NASDAQ:BIOC) www.investornewswire.com - September 24 at 8:05 AM
	Biocept's Proprietary Liquid Biopsy Platform to be Featured at Two ... - PR Newswire (press release) (NASDAQ:BIOC) www.prnewswire.com - September 23 at 3:18 PM
	Keen Investors Find News on Biocept, Inc. (NASDAQ:BIOC) - Duncan Research (NASDAQ:BIOC) www.duncanindependent.com - September 23 at 3:18 PM
	Biocept's Proprietary Liquid Biopsy Platform to be Featured at Two Upcoming Molecular Diagnostics Conferences (NASDAQ:BIOC) finance.yahoo.com - September 23 at 3:18 PM
	ETF’s with exposure to Biocept, Inc. : September 23, 2016 (NASDAQ:BIOC) www.capitalcube.com - September 23 at 3:18 PM
	Under the Microscope, Zeroing in at Biocept, Inc. (NASDAQ:BIOC) - Duncan Research (NASDAQ:BIOC) www.duncanindependent.com - September 22 at 4:00 PM
	Stock Update: Estimates & Target in Focus for Biocept, Inc. (NASDAQ:BIOC) - Frisco Fastball (NASDAQ:BIOC) friscofastball.com - September 22 at 8:04 AM
	Global Circulating Tumor Cell Market Key Players - Viatar CTC Solutions Inc., BIOCEPT, INC. (San Diego), Grail Bio ... - Yahoo Finance (NASDAQ:BIOC) finance.yahoo.com - September 21 at 8:23 AM
	Penny Stock Investors Take an Interest in Biocept, Inc. (NASDAQ:BIOC) - Duncan Research (NASDAQ:BIOC) www.duncanindependent.com - September 21 at 8:23 AM
	GSK names Emma Walmsley as new chief executive (NASDAQ:BIOC) sg.finance.yahoo.com - September 20 at 9:06 AM
	Increased number of pregnancies are driving the Cell-Free DNA (cfDNA) Testing Market growth (NASDAQ:BIOC) www.openpr.com - September 19 at 8:36 AM
	Expected For Biocept, Inc. (NASDAQ:BIOC) Sales Of $11.94 - Investor Newswire (NASDAQ:BIOC) www.investornewswire.com - September 16 at 3:47 PM
	Dr. Shilpa Gupta to study liquid biopsy testing in bladder cancers (NASDAQ:BIOC) www.canindia.com - September 12 at 3:45 PM
	Biocept, Inc. (NASDAQ:BIOC) Expects Sales Of $11.94 - Investor Newswire (NASDAQ:BIOC) www.investornewswire.com - September 10 at 8:34 AM
	Biocept to Collaborate with Renowned Clinical Investigator Dr. Shilpa Gupta to Study the Utility of Liquid Biopsy ... - PR Newswire (press release) (NASDAQ:BIOC) www.prnewswire.com - September 10 at 8:34 AM
	Company Update (NASDAQ:BIOC): Biocept Inc to Collaborate with Renowned Clinical Investigator Dr. Shilpa Gupta to ... - Smarter Analyst (NASDAQ:BIOC) www.smarteranalyst.com - September 9 at 3:45 PM
	Biocept to Collaborate with Renowned Clinical Investigator Dr. Shilpa Gupta to Study the Utility of Liquid … (NASDAQ:BIOC) finance.yahoo.com - September 9 at 8:40 AM
	Biocept to Collaborate with Renowned Clinical Investigator Dr. Shilpa Gupta to Study the Utility of Liquid Biopsy Testing in Bladder and Prostate Cancers (NASDAQ:BIOC) www.publicnow.com - September 9 at 8:40 AM
	What are Research Firms Saying About Biocept, Inc. (NASDAQ:BIOC)? - Frisco Fastball (NASDAQ:BIOC) friscofastball.com - September 8 at 8:16 AM
	Global Cell-Free DNA Testing Market Driven by Increasing Incidences of Diseases Like Chromosomal Abnormalities (NASDAQ:BIOC) reports.pr-inside.com - September 6 at 8:39 AM
	Biocept Announces Agreement with Teneovita Medical to Market and Distribute its Liquid Biopsy Testing Platform in ... - PR Newswire (press release) (NASDAQ:BIOC) www.prnewswire.com - September 1 at 3:49 PM
	Rodman & Renshaw Bullish on Biocept Inc (BIOC) Following Fourth International Expansion - Smarter Analyst (NASDAQ:BIOC) www.smarteranalyst.com - September 1 at 3:49 PM
	Teneovita to market & distribute Biocept's liquid biopsy testing services in Canada (NASDAQ:BIOC) www.pharmabiz.com - September 1 at 12:17 PM
	Biocept Expands Chinese Patent Protection Covering Key Technologies for Circulating Tumor Cell Capture and (NASDAQ:BIOC) www.biomedreports.com - September 1 at 12:17 PM
	Biocept Expands Chinese Patent Protection Covering Key Technologies for Circulating Tumor Cell Capture and Analysis Used in Liquid Biopsy Tests (NASDAQ:BIOC) www.publicnow.com - September 1 at 12:17 PM
	BRIEF-Biocept reports agreement with Teneovita Medical - Reuters (NASDAQ:BIOC) in.reuters.com - August 31 at 3:49 PM
	Biocept Inc. Announces Deal With Teneovita for Marketing, Distributing Diagnostic in Canada (NASDAQ:BIOC) sdbj.com - August 31 at 8:37 AM
	BRIEF-Biocept reports agreement with Teneovita Medical (NASDAQ:BIOC) www.reuters.com - August 30 at 3:48 PM
	Biocept (BIOC) Enters Preferred Provider Agreement with Teneovita Medical (NASDAQ:BIOC) www.streetinsider.com - August 30 at 3:48 PM
	Biocept, Inc. Announces Agreement With To Market And Distribute Its Liquid Biopsy Testing Platform In Canada (NASDAQ:BIOC) www.biospace.com - August 30 at 3:48 PM
	Biocept Announces Agreement with Teneovita Medical to Market and Distribute its Liquid Biopsy Testing Platform in Canada (NASDAQ:BIOC) finance.yahoo.com - August 30 at 8:13 AM
	Will Biocept, Inc. (NASDAQ:BIOC) miss earning estimates again ... - The Independent Republic (NASDAQ:BIOC) theindependentrepublic.com - August 27 at 3:46 PM
	New Market Report: Biocept, Inc. (BIOC) - Financial and Strategic SWOT Analysis Review (NASDAQ:BIOC) www.live-pr.com - August 26 at 3:48 PM
	Stock's Buzz: Biocept, Inc. (NASDAQ:BIOC), NorthStar Asset Management Group, Inc. (NYSE:NSAM) - Newburg Press (NASDAQ:BIOC) newburghpress.com - August 24 at 3:50 PM
	Stocks Trapped in Bearish Claws: EnteroMedics Inc. (NASDAQ:ETRM), Biocept, Inc. (NASDAQ:BIOC) - Street Wise Report (press release) (blog) (NASDAQ:BIOC) streetwisereport.com - August 24 at 12:04 PM
	ETF’s with exposure to Biocept, Inc. : August 23, 2016 (NASDAQ:BIOC) www.capitalcube.com - August 23 at 3:52 PM
	Will Biocept, Inc. (NASDAQ:BIOC) Hit $2.5 Price Target? - Investor Newswire (NASDAQ:BIOC) www.investornewswire.com - August 21 at 8:33 AM
	Biocept to Present at Next Generation Dx Summit (NASDAQ:BIOC) www.publicnow.com - August 18 at 12:15 PM
	Report Published: "Liquid Biopsy Market - Forecast to 2021" (NASDAQ:BIOC) www.sbwire.com - August 17 at 12:02 PM
	BIOCEPT INC Financials (NASDAQ:BIOC) finance.yahoo.com - August 13 at 3:50 PM
	ETF’s with exposure to Biocept, Inc. : August 12, 2016 (NASDAQ:BIOC) www.capitalcube.com - August 12 at 4:03 PM
	Biocept Inc. Signs Distribution Deal for Philippines (NASDAQ:BIOC) sdbj.com - August 11 at 9:43 PM
	BRIEF-Biocept expands distribution of liquid biopsy tests to Philippines (NASDAQ:BIOC) www.reuters.com - August 11 at 12:00 PM
	Biocept Expands Distribution of Liquid Biopsy Tests to the Philippines (NASDAQ:BIOC) www.publicnow.com - August 11 at 11:59 AM
	Biocept, Inc. :BIOC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 (NASDAQ:BIOC) www.capitalcube.com - August 9 at 4:57 PM
	BIOCEPT INC Files SEC form 10-Q, Quarterly Report (NASDAQ:BIOC) biz.yahoo.com - August 5 at 9:13 PM
	San Diego Entrepreneurs Launch Innovative E-Commerce Health Care Company (NASDAQ:BIOC) cad.digitalmedianet.com - August 4 at 3:57 PM
	Biocept Inc.: Biocept Reports 2016 Second Quarter Financial Results (NASDAQ:BIOC) www.twst.com - August 3 at 9:31 PM
	Analyst Ratings On Watch List: Biocept Inc (NASDAQ:BIOC ... - Review Fortune (NASDAQ:BIOC) reviewfortune.com - August 3 at 3:53 PM